25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

TERN (Terns Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Terns Pharmaceuticals Inc together

I guess you are interested in Terns Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Terns Pharmaceuticals Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Terns Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Terns Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Terns Pharmaceuticals Inc

I send you an email if I find something interesting about Terns Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Terns Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Terns Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.56
Expected worth in 1 year
$4.42
How sure are you?
31.8%

+ What do you gain per year?

Total Gains per Share
$0.85
Return On Investment
19.8%

For what price can you sell your share?

Current Price per Share
$4.32
Expected price per share
$3.62 - $5.46
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Terns Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$4.32
Intrinsic Value Per Share
$-10.85 - $-12.75
Total Value Per Share
$-7.29 - $-9.18

2.2. Growth of Terns Pharmaceuticals Inc (5 min.)




Is Terns Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$326m$256.1m$57.6m18.4%

How much money is Terns Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$22.5m-$22.7m$166.7k0.7%
Net Profit Margin0.0%-397.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Terns Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#183 / 881

Most Revenue
#788 / 881

Most Profit
#664 / 881

Most Efficient
#197 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Terns Pharmaceuticals Inc?

Welcome investor! Terns Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Terns Pharmaceuticals Inc.

First you should know what it really means to hold a share of Terns Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Terns Pharmaceuticals Inc is $4.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Terns Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Terns Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.56. Based on the TTM, the Book Value Change Per Share is $0.21 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Terns Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.26-6.1%-0.25-5.9%-0.26-6.0%-0.24-5.5%-0.19-4.4%-0.18-4.2%
Usd Book Value Change Per Share-0.23-5.2%0.214.9%-0.15-3.4%0.163.6%0.184.1%0.163.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.23-5.2%0.214.9%-0.15-3.4%0.163.6%0.184.1%0.163.8%
Usd Price Per Share2.76-5.86-6.71-6.72-6.77-6.15-
Price to Earnings Ratio-2.64--5.82--6.90--7.38--9.21--8.38-
Price-to-Total Gains Ratio-12.19--13.66--75.12--21.42--31.67--31.67-
Price to Book Ratio0.77-1.74-2.28-2.27-2.71-2.46-
Price-to-Total Gains Ratio-12.19--13.66--75.12--21.42--31.67--31.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.32
Number of shares231
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.210.18
Usd Total Gains Per Share0.210.18
Gains per Quarter (231 shares)49.3140.61
Gains per Year (231 shares)197.26162.45
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101971870162152
203953840325314
305925810487476
407897780650638
509869750812800
60118411720975962
7013811369011371124
8015781566013001286
9017751763014621448
10019731960016241610

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.021.00.04.5%1.021.00.04.5%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.013.01.030.0%7.013.02.031.8%7.013.02.031.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.013.01.030.0%7.013.02.031.8%7.013.02.031.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Terns Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2260.213-206%-0.146-36%0.155-246%0.176-229%0.162-240%
Book Value Per Share--3.5643.508+2%2.933+22%2.992+19%2.311+54%2.105+69%
Current Ratio--30.88727.008+14%23.217+33%25.685+20%22.196+39%20.382+52%
Debt To Asset Ratio--0.0390.044-12%0.048-19%0.046-15%0.214-82%0.269-85%
Debt To Equity Ratio--0.0410.047-13%0.050-19%0.048-15%0.111-63%0.363-89%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--573460096.480828579561.120-31%836891293.500-31%848632846.707-32%929321269.205-38%929321269.205-38%
Eps---0.261-0.253-3%-0.2600%-0.236-10%-0.190-27%-0.182-30%
Ev To Ebitda Ratio---5.227-8.104+55%-8.472+62%-9.495+82%-13.399+156%-13.399+156%
Free Cash Flow Per Share---0.267-0.200-25%-0.217-19%-0.187-30%-0.157-41%-0.152-43%
Free Cash Flow To Equity Per Share---0.2660.269-199%-0.176-34%0.170-257%0.183-246%0.157-270%
Gross Profit Margin--1.0001.0030%1.005-1%1.0030%1.0020%1.0010%
Intrinsic Value_10Y_max---12.746----------
Intrinsic Value_10Y_min---10.852----------
Intrinsic Value_1Y_max---0.826----------
Intrinsic Value_1Y_min---0.811----------
Intrinsic Value_3Y_max---2.826----------
Intrinsic Value_3Y_min---2.691----------
Intrinsic Value_5Y_max---5.240----------
Intrinsic Value_5Y_min---4.834----------
Market Cap377299296.000+33%252468096.480520277311.120-51%585818293.500-57%589881513.373-57%592885128.824-57%538986480.749-53%
Net Profit Margin----0%-3.9750%-1.3250%-310790.3960%-282536.7240%
Operating Margin----0%-4.5780%-1.5260%-311726.6090%-283387.8270%
Operating Ratio----0%4.550-100%1.517-100%314566.937-100%285969.943-100%
Pb Ratio1.212+36%0.7741.739-55%2.282-66%2.272-66%2.708-71%2.462-69%
Pe Ratio-4.132-57%-2.640-5.819+120%-6.899+161%-7.378+179%-9.213+249%-8.375+217%
Price Per Share4.320+36%2.7605.863-53%6.708-59%6.723-59%6.770-59%6.154-55%
Price To Free Cash Flow Ratio-4.042-57%-2.583-7.874+205%-8.401+225%-9.772+278%-11.403+342%-10.367+301%
Price To Total Gains Ratio-19.080-57%-12.190-13.663+12%-75.122+516%-21.424+76%-31.672+160%-31.672+160%
Quick Ratio--48.42339.579+22%39.995+21%40.609+19%35.285+37%32.325+50%
Return On Assets---0.070-0.072+2%-0.085+21%-0.078+11%-0.123+75%-0.148+110%
Return On Equity---0.073-0.075+2%-0.089+22%-0.082+12%-0.102+39%-0.220+201%
Total Gains Per Share---0.2260.213-206%-0.146-36%0.155-246%0.176-229%0.162-240%
Usd Book Value--326043000.000313766000.000+4%256165500.000+27%263771833.333+24%203286100.000+60%185188000.000+76%
Usd Book Value Change Per Share---0.2260.213-206%-0.146-36%0.155-246%0.176-229%0.162-240%
Usd Book Value Per Share--3.5643.508+2%2.933+22%2.992+19%2.311+54%2.105+69%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--573460096.480828579561.120-31%836891293.500-31%848632846.707-32%929321269.205-38%929321269.205-38%
Usd Eps---0.261-0.253-3%-0.2600%-0.236-10%-0.190-27%-0.182-30%
Usd Free Cash Flow---24440000.000-17917750.000-27%-18971750.000-22%-16481833.333-33%-13808350.000-44%-13349636.364-45%
Usd Free Cash Flow Per Share---0.267-0.200-25%-0.217-19%-0.187-30%-0.157-41%-0.152-43%
Usd Free Cash Flow To Equity Per Share---0.2660.269-199%-0.176-34%0.170-257%0.183-246%0.157-270%
Usd Market Cap377299296.000+33%252468096.480520277311.120-51%585818293.500-57%589881513.373-57%592885128.824-57%538986480.749-53%
Usd Price Per Share4.320+36%2.7605.863-53%6.708-59%6.723-59%6.770-59%6.154-55%
Usd Profit---23908000.000-22597000.000-5%-22763750.000-5%-20795250.000-13%-17226300.000-28%-16513727.273-31%
Usd Revenue----0%330500.000-100%110166.667-100%116101.900-100%105547.182-100%
Usd Total Gains Per Share---0.2260.213-206%-0.146-36%0.155-246%0.176-229%0.162-240%
 EOD+5 -3MRQTTM+13 -20YOY+14 -213Y+14 -215Y+14 -2110Y+14 -21

3.3 Fundamental Score

Let's check the fundamental score of Terns Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.132
Price to Book Ratio (EOD)Between0-11.212
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than148.423
Current Ratio (MRQ)Greater than130.887
Debt to Asset Ratio (MRQ)Less than10.039
Debt to Equity Ratio (MRQ)Less than10.041
Return on Equity (MRQ)Greater than0.15-0.073
Return on Assets (MRQ)Greater than0.05-0.070
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Terns Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.960
Ma 20Greater thanMa 503.913
Ma 50Greater thanMa 1003.422
Ma 100Greater thanMa 2003.319
OpenGreater thanClose4.300
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Terns Pharmaceuticals Inc

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Fundamental data was last updated by Penke on 2025-06-20 17:25:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Terns Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Terns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Terns Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-397.5%+397.5%
TTM-5Y-31,079,039.6%+31,079,039.6%
5Y-31,079,039.6%10Y-28,253,672.4%-2,825,367.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM--139.0%+139.0%
YOY-397.5%-194.4%-203.1%
3Y-132.5%-248.5%+116.0%
5Y-31,079,039.6%-343.3%-31,078,696.3%
10Y-28,253,672.4%-488.9%-28,253,183.5%
4.3.1.2. Return on Assets

Shows how efficient Terns Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Terns Pharmaceuticals Inc to the Biotechnology industry mean.
  • -7.0% Return on Assets means that Terns Pharmaceuticals Inc generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Terns Pharmaceuticals Inc:

  • The MRQ is -7.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.0%TTM-7.2%+0.1%
TTM-7.2%YOY-8.5%+1.3%
TTM-7.2%5Y-12.3%+5.2%
5Y-12.3%10Y-14.8%+2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.0%-11.6%+4.6%
TTM-7.2%-11.7%+4.5%
YOY-8.5%-11.4%+2.9%
3Y-7.8%-11.9%+4.1%
5Y-12.3%-12.1%-0.2%
10Y-14.8%-13.8%-1.0%
4.3.1.3. Return on Equity

Shows how efficient Terns Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Terns Pharmaceuticals Inc to the Biotechnology industry mean.
  • -7.3% Return on Equity means Terns Pharmaceuticals Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Terns Pharmaceuticals Inc:

  • The MRQ is -7.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.3%TTM-7.5%+0.2%
TTM-7.5%YOY-8.9%+1.4%
TTM-7.5%5Y-10.2%+2.7%
5Y-10.2%10Y-22.0%+11.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.3%-13.5%+6.2%
TTM-7.5%-15.0%+7.5%
YOY-8.9%-14.5%+5.6%
3Y-8.2%-16.9%+8.7%
5Y-10.2%-17.9%+7.7%
10Y-22.0%-19.9%-2.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Terns Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Terns Pharmaceuticals Inc is operating .

  • Measures how much profit Terns Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Terns Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Terns Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-457.8%+457.8%
TTM-5Y-31,172,660.9%+31,172,660.9%
5Y-31,172,660.9%10Y-28,338,782.7%-2,833,878.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--249.7%+249.7%
YOY-457.8%-208.4%-249.4%
3Y-152.6%-221.7%+69.1%
5Y-31,172,660.9%-344.1%-31,172,316.8%
10Y-28,338,782.7%-470.4%-28,338,312.3%
4.3.2.2. Operating Ratio

Measures how efficient Terns Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Terns Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY4.550-4.550
TTM-5Y314,566.937-314,566.937
5Y314,566.93710Y285,969.943+28,596.994
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM-2.680-2.680
YOY4.5503.080+1.470
3Y1.5173.621-2.104
5Y314,566.9374.734+314,562.203
10Y285,969.9436.546+285,963.397
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Terns Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Terns Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 30.89 means the company has $30.89 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Terns Pharmaceuticals Inc:

  • The MRQ is 30.887. The company is very able to pay all its short-term debts. +2
  • The TTM is 27.008. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ30.887TTM27.008+3.878
TTM27.008YOY23.217+3.791
TTM27.0085Y22.196+4.812
5Y22.19610Y20.382+1.814
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ30.8873.659+27.228
TTM27.0083.834+23.174
YOY23.2174.141+19.076
3Y25.6854.661+21.024
5Y22.1965.756+16.440
10Y20.3826.151+14.231
4.4.3.2. Quick Ratio

Measures if Terns Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Terns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 48.42 means the company can pay off $48.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Terns Pharmaceuticals Inc:

  • The MRQ is 48.423. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 39.579. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ48.423TTM39.579+8.843
TTM39.579YOY39.995-0.416
TTM39.5795Y35.285+4.294
5Y35.28510Y32.325+2.960
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ48.4232.799+45.624
TTM39.5793.143+36.436
YOY39.9953.794+36.201
3Y40.6094.307+36.302
5Y35.2855.707+29.578
10Y32.3256.457+25.868
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Terns Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Terns Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Terns Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Terns Pharmaceuticals Inc assets are financed with 3.9% credit (debt) and the remaining percentage (100% - 3.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Terns Pharmaceuticals Inc:

  • The MRQ is 0.039. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.044. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.039TTM0.044-0.005
TTM0.044YOY0.048-0.004
TTM0.0445Y0.214-0.169
5Y0.21410Y0.269-0.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0390.324-0.285
TTM0.0440.347-0.303
YOY0.0480.329-0.281
3Y0.0460.340-0.294
5Y0.2140.349-0.135
10Y0.2690.379-0.110
4.5.4.2. Debt to Equity Ratio

Measures if Terns Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Terns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.1% means that company has $0.04 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Terns Pharmaceuticals Inc:

  • The MRQ is 0.041. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.047. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.041TTM0.047-0.006
TTM0.047YOY0.050-0.004
TTM0.0475Y0.111-0.065
5Y0.11110Y0.363-0.252
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0410.379-0.338
TTM0.0470.435-0.388
YOY0.0500.412-0.362
3Y0.0480.446-0.398
5Y0.1110.460-0.349
10Y0.3630.509-0.146
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Terns Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Terns Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -2.64 means the investor is paying $-2.64 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Terns Pharmaceuticals Inc:

  • The EOD is -4.132. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.640. Based on the earnings, the company is expensive. -2
  • The TTM is -5.819. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.132MRQ-2.640-1.492
MRQ-2.640TTM-5.819+3.179
TTM-5.819YOY-6.899+1.080
TTM-5.8195Y-9.213+3.394
5Y-9.21310Y-8.375-0.838
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.132-2.282-1.850
MRQ-2.640-2.062-0.578
TTM-5.819-2.541-3.278
YOY-6.899-3.722-3.177
3Y-7.378-3.754-3.624
5Y-9.213-6.100-3.113
10Y-8.375-6.653-1.722
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Terns Pharmaceuticals Inc:

  • The EOD is -4.042. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.583. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.874. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.042MRQ-2.583-1.460
MRQ-2.583TTM-7.874+5.292
TTM-7.874YOY-8.401+0.526
TTM-7.8745Y-11.403+3.529
5Y-11.40310Y-10.367-1.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.042-3.101-0.941
MRQ-2.583-2.689+0.106
TTM-7.874-3.594-4.280
YOY-8.401-4.363-4.038
3Y-9.772-5.065-4.707
5Y-11.403-8.478-2.925
10Y-10.367-9.273-1.094
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Terns Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.77 means the investor is paying $0.77 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Terns Pharmaceuticals Inc:

  • The EOD is 1.212. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.774. Based on the equity, the company is cheap. +2
  • The TTM is 1.739. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.212MRQ0.774+0.438
MRQ0.774TTM1.739-0.964
TTM1.739YOY2.282-0.543
TTM1.7395Y2.708-0.970
5Y2.70810Y2.462+0.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2121.932-0.720
MRQ0.7741.848-1.074
TTM1.7392.119-0.380
YOY2.2822.469-0.187
3Y2.2722.526-0.254
5Y2.7083.667-0.959
10Y2.4624.351-1.889
4.6.2. Total Gains per Share

2.4. Latest News of Terns Pharmaceuticals Inc

Does Terns Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Terns Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-26
00:13
Terns pharmaceuticals CEO Burroughs buys $90k in sharesRead
2025-06-23
22:13
Terns completes enrollment in Phase 2 obesity drug trialRead
2025-06-23
22:07
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific SessionsRead
2025-06-17
11:00
Citizens JMP reiterates Terns Pharmaceuticals stock rating on positive dataRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Terns Pharmaceuticals Inc.

4.8.1. Institutions holding Terns Pharmaceuticals Inc

Institutions are holding 100% of the shares of Terns Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Soleus Capital Management, L.P.9.35121.62298167100246000.3021
2025-03-31Orbimed Advisors, LLC8.65940.4976756297100
2025-03-31Morgan Stanley - Brokerage Accounts8.14090.001471101053762298112.381
2025-03-31Vivo Capital, LLC7.89552.5206689574600
2025-03-31BlackRock Inc6.5340.00035706632-36850-0.6416
2025-03-31Deep Track Capital, LP6.3850.4984557655800
2024-12-31Schonfeld Strategic Advisors LLC5.44040.15314751506146168044.4303
2025-03-31Vanguard Group Inc4.75410.000241521562825747.3024
2025-03-31Citadel Advisors Llc4.47450.0021390788764010819.5885
2024-12-31Nuveen Asset Management, LLC3.01580.0041263391861700930.5918
2025-03-31Candriam Luxembourg S.C.A.2.46630.0372215396900
2025-03-31Dimensional Fund Advisors, Inc.1.95360.0012170620140326930.9509
2025-03-31Geode Capital Management, LLC1.80240.00031574204577263.8066
2025-03-31Renaissance Technologies Corp1.64170.0061433834810700130.1004
2025-03-31Nuveen, LLC1.60970.0012140590114059010
2025-03-31SUPERSTRING CAPITAL MANAGEMENT LP1.55394.45671357153-663409-32.8329
2025-03-31State Street Corp1.51650.00021324517374742.9116
2025-03-31Millennium Management LLC1.27940.00161117442-492773-30.6029
2025-03-31Parkman Healthcare Partners LLC1.09880.314295970313059815.7517
2024-12-31NORGES BANK0.97250.00068493898493890
Total 80.545610.119970346892+9290294+13.2%

4.9.2. Funds holding Terns Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv2.48530.00042170595985594.7566
2025-05-31iShares Russell 2000 ETF2.01950.0089176382000
2025-05-31Belfius Equities Cure C Cap1.47150.2715128514800
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.07280.00393696800
2025-04-30Candriam Eqs L Biotech C USD Cap0.99470.240886873300
2025-04-30Nuveen Quant Small Cap Equity R60.93480.0875816464-20310-2.4272
2025-05-31Franklin Biotechnology Discv A(acc)USD0.87890.19097675907109901256.1661
2025-03-31Fidelity Small Cap Index0.80490.008702984-149-0.0212
2025-03-31HBM Healthcare Investments AG Ord0.76940.092667197500
2025-05-31iShares Russell 2000 Value ETF0.67540.017158989600
2025-04-30International Biotechnology Ord0.43070.427537620400
2025-05-31iShares Biotechnology ETF0.42430.023137059500
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.41960.002836650000
2025-04-30Vanguard Russell 2000 ETF0.40780.0099356159292908.9608
2025-04-30DWS ESG Biotech LC0.39270.3262342976-6-0.0017
2025-03-31Vanguard Explorer Inv0.38720.004733816715883588.5704
2025-04-30Fidelity Extended Market Index0.36830.003321702-3075-0.9468
2025-04-30DFA US Small Cap I0.32840.006428683000
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.31340.0098273700103003.9104
2025-05-30Dimensional US Small Cap ETF0.25770.007222505300
Total 15.83731.741313832059+984434+7.1%

5.3. Insider Transactions

Insiders are holding 0.251% of the shares of Terns Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-16Andrew GengosBUY50003.95
2025-06-13Andrew GengosBUY100003.73
2025-04-01Emil KuriakoseSELL9522.49
2025-01-06Jill M. QuigleySELL87605.79
2025-01-06Mark J VignolaSELL90595.8
2025-01-02Emil KuriakoseSELL44815.71
2025-01-02Jill M QuigleySELL62405.72
2025-01-02Mark J VignolaSELL81295.72
2024-12-05Amy L BurroughsBUY154507.15
2024-11-30Amy L BurroughsBUY5105.11
2024-11-30Melita Sun JungBUY22505.11
2024-09-12Hongbo LuBUY47619010.5
2024-09-10Mark J VignolaSELL1000011
2024-09-09Jill M QuigleySELL1723510
2024-08-01Jill M QuigleySELL61437.68
2024-07-15Carl L GordonSELL5097610
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Income Tax Expense  97-3661162-2240-128-88



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets339,315
Total Liabilities13,272
Total Stockholder Equity326,043
 As reported
Total Liabilities 13,272
Total Stockholder Equity+ 326,043
Total Assets = 339,315

Assets

Total Assets339,315
Total Current Assets337,748
Long-term Assets1,567
Total Current Assets
Cash And Cash Equivalents 139,023
Short-term Investments 195,241
Other Current Assets 3,484
Total Current Assets  (as reported)337,748
Total Current Assets  (calculated)337,748
+/-0
Long-term Assets
Property Plant Equipment 1,216
Long-term Assets Other 351
Long-term Assets  (as reported)1,567
Long-term Assets  (calculated)1,567
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,935
Long-term Liabilities2,337
Total Stockholder Equity326,043
Total Current Liabilities
Short-term Debt 429
Accounts payable 2,778
Other Current Liabilities 1,888
Total Current Liabilities  (as reported)10,935
Total Current Liabilities  (calculated)5,095
+/- 5,840
Long-term Liabilities
Capital Lease Obligations 1,235
Long-term Liabilities  (as reported)2,337
Long-term Liabilities  (calculated)1,235
+/- 1,102
Total Stockholder Equity
Common Stock9
Retained Earnings -445,389
Accumulated Other Comprehensive Income 51
Other Stockholders Equity 771,372
Total Stockholder Equity (as reported)326,043
Total Stockholder Equity (calculated)326,043
+/-0
Other
Capital Stock9
Cash and Short Term Investments 334,264
Common Stock Shares Outstanding 91,474
Liabilities and Stockholders Equity 339,315
Net Debt -137,788
Net Invested Capital 326,043
Net Working Capital 326,813
Property Plant and Equipment Gross 1,216
Short Long Term Debt Total 1,235



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
23,904
0
0
17,413
92,290
199,241
188,007
179,890
168,070
156,669
144,860
192,586
287,026
301,285
289,697
271,687
268,517
246,766
230,880
378,233
363,929
339,315
339,315363,929378,233230,880246,766268,517271,687289,697301,285287,026192,586144,860156,669168,070179,890188,007199,24192,29017,4130023,904
   > Total Current Assets 
22,224
19,650
0
15,421
90,869
198,042
186,872
178,794
166,930
154,111
142,601
190,537
285,185
297,526
288,315
270,455
267,432
245,895
230,238
376,506
362,109
337,748
337,748362,109376,506230,238245,895267,432270,455288,315297,526285,185190,537142,601154,111166,930178,794186,872198,04290,86915,421019,65022,224
       Cash And Cash Equivalents 
12,327
-19,650
0
13,756
74,854
98,829
67,589
64,751
47,699
43,879
16,806
62,977
143,235
184,354
80,919
37,893
79,926
65,099
91,496
270,136
161,439
139,023
139,023161,439270,13691,49665,09979,92637,89380,919184,354143,23562,97716,80643,87947,69964,75167,58998,82974,85413,7560-19,65012,327
       Short-term Investments 
7,323
39,300
0
0
0
96,752
117,495
112,445
118,283
107,389
123,004
124,309
139,879
113,172
204,684
228,707
183,514
175,555
133,801
102,641
196,725
195,241
195,241196,725102,641133,801175,555183,514228,707204,684113,172139,879124,309123,004107,389118,283112,445117,49596,75200039,3007,323
       Net Receivables 
0
0
0
0
12,718
12,718
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000012,71812,7180000
       Other Current Assets 
2,574
0
0
1,665
3,297
4,922
3,576
3,196
1,896
5,686
5,582
6,502
2,071
2,138
2,712
3,855
3,992
5,241
4,941
3,729
3,945
3,484
3,4843,9453,7294,9415,2413,9923,8552,7122,1382,0716,5025,5825,6861,8963,1963,5764,9223,2971,665002,574
   > Long-term Assets 
1,680
-19,650
0
1,992
1,421
1,199
1,135
1,096
1,140
2,558
2,259
2,049
1,841
3,759
1,382
1,232
1,085
871
642
1,727
1,820
1,567
1,5671,8201,7276428711,0851,2321,3823,7591,8412,0492,2592,5581,1401,0961,1351,1991,4211,9920-19,6501,680
       Property Plant Equipment 
961
0
0
1,234
1,175
1,025
959
927
1,046
2,486
2,195
2,002
1,804
1,584
1,346
1,197
1,029
816
587
1,671
1,470
1,216
1,2161,4701,6715878161,0291,1971,3461,5841,8042,0022,1952,4861,0469279591,0251,1751,23400961
       Other Assets 
719
0
0
0
246
174
176
169
94
72
64
47
37
0
36
0
0
0
0
0
0
0
00000003603747647294169176174246000719
> Total Liabilities 
19,697
0
0
42,261
23,698
9,239
6,675
7,734
7,767
7,953
7,644
8,892
10,083
13,602
15,547
13,262
13,150
10,046
12,199
13,763
18,059
13,272
13,27218,05913,76312,19910,04613,15013,26215,54713,60210,0838,8927,6447,9537,7677,7346,6759,23923,69842,2610019,697
   > Total Current Liabilities 
4,950
0
0
28,023
22,821
8,377
5,818
6,893
6,820
6,165
6,044
7,481
8,468
12,109
14,238
12,087
11,944
8,828
10,955
11,412
15,650
10,935
10,93515,65011,41210,9558,82811,94412,08714,23812,1098,4687,4816,0446,1656,8206,8935,8188,37722,82128,023004,950
       Short-term Debt 
0
0
0
19,337
12,880
3,208
3,163
4,392
0
1,168
1,172
1,330
661
1,312
1,306
707
1,206
427
498
272
428
429
4294282724984271,2067071,3061,3126611,3301,1721,16804,3923,1633,20812,88019,337000
       Short Long Term Debt 
0
0
0
19,337
12,880
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000012,88019,337000
       Accounts payable 
1,636
0
0
461
935
4,250
1,688
1,582
2,126
1,678
973
2,094
1,645
2,690
5,537
3,325
2,515
1,701
1,873
1,787
2,148
2,778
2,7782,1481,7871,8731,7012,5153,3255,5372,6901,6452,0949731,6782,1261,5821,6884,250935461001,636
       Other Current Liabilities 
3,314
0
0
8,225
7,513
2,637
2,630
3,810
3,907
2,531
3,150
3,348
5,091
7,000
6,309
8,055
7,017
5,482
7,340
8,035
13,074
1,888
1,88813,0748,0357,3405,4827,0178,0556,3097,0005,0913,3483,1502,5313,9073,8102,6302,6377,5138,225003,314
   > Long-term Liabilities 
14,747
0
0
14,238
877
862
857
841
947
1,788
1,600
1,411
1,615
1,493
1,309
1,175
1,206
1,218
1,244
2,351
2,409
2,337
2,3372,4092,3511,2441,2181,2061,1751,3091,4931,6151,4111,6001,78894784185786287714,2380014,747
       Other Liabilities 
630
0
0
0
877
862
857
841
947
788
749
709
1,071
0
1,086
0
0
0
0
0
0
0
00000001,08601,071709749788947841857862877000630
       Deferred Long Term Liability 
0
0
0
0
0
208
193
176
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000017619320800000
> Total Stockholder Equity
4,207
18,324
0
-24,848
68,592
190,002
181,332
172,156
160,303
148,716
137,216
183,694
276,943
287,683
274,150
258,425
255,367
236,720
218,681
364,470
345,870
326,043
326,043345,870364,470218,681236,720255,367258,425274,150287,683276,943183,694137,216148,716160,303172,156181,332190,00268,592-24,848018,3244,207
   Common Stock
0
0
0
0
0
3
3
3
3
3
3
4
5
5
6
6
6
6
7
8
9
9
9987666655433333300000
   Retained Earnings Total Equity0000000-281,842-263,946-242,418-226,596-209,77600-167,825-155,990-145,25200000
   Accumulated Other Comprehensive Income 
-106
-90,760
0
90
-124
-232
-174
-167
-338
-896
-1,241
-1,348
-822
-416
-775
-836
-19
-321
-443
160
-279
51
51-279160-443-321-19-836-775-416-822-1,348-1,241-896-338-167-174-232-124900-90,760-106
   Capital Surplus 
0
0
0
0
0
335,483
337,493
340,145
0
0
348,230
411,634
520,178
552,040
556,761
0
0
0
0
0
0
0
0000000556,761552,040520,178411,634348,23000340,145337,493335,48300000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
1,208
14,117
0
2,081
14,598
335,483
337,493
340,145
342,711
345,455
348,230
411,634
520,178
552,040
556,761
570,864
588,008
592,036
596,854
763,984
767,621
771,372
771,372767,621763,984596,854592,036588,008570,864556,761552,040520,178411,634348,230345,455342,711340,145337,493335,48314,5982,081014,1171,208



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-101,871
Operating Income-101,871-101,871
 
Operating Expense (+$)
Research Development70,112
Selling General Administrative31,759
Selling And Marketing Expenses0
Operating Expense101,871101,871
 
Net Interest Income (+$)
Interest Income13,289
Interest Expense-0
Other Finance Cost-0
Net Interest Income13,289
 
Pretax Income (+$)
Operating Income-101,871
Net Interest Income13,289
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-88,593-115,149
EBIT - interestExpense = -88,593
-88,593
-88,853
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-88,593-88,593
Earnings Before Interest and Taxes (EBITDA)-87,697
 
After tax Income (+$)
Income Before Tax-88,593
Tax Provision-260
Net Income From Continuing Ops-88,853-88,853
Net Income-88,853
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net13,278-13,289
 

Technical Analysis of Terns Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Terns Pharmaceuticals Inc. The general trend of Terns Pharmaceuticals Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Terns Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Terns Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Terns Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 4.34 < 4.765 < 5.46.

The bearish price targets are: 3.72 > 3.7 > 3.62.

Know someone who trades $TERN? Share this with them.👇

Terns Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Terns Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Terns Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Terns Pharmaceuticals Inc. The current macd is 0.19997003.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Terns Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Terns Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Terns Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Terns Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartTerns Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Terns Pharmaceuticals Inc. The current adx is 32.15.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Terns Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Terns Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Terns Pharmaceuticals Inc. The current sar is 3.5668.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Terns Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Terns Pharmaceuticals Inc. The current rsi is 65.96. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Terns Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartTerns Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Terns Pharmaceuticals Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Terns Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Terns Pharmaceuticals Inc Daily Stochastic Oscillator ChartTerns Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Terns Pharmaceuticals Inc. The current cci is 179.22.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Terns Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartTerns Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Terns Pharmaceuticals Inc. The current cmo is 36.33.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Terns Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartTerns Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Terns Pharmaceuticals Inc. The current willr is -8.33333333.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Terns Pharmaceuticals Inc Daily Williams %R ChartTerns Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Terns Pharmaceuticals Inc.

Terns Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Terns Pharmaceuticals Inc. The current atr is 0.29784904.

Terns Pharmaceuticals Inc Daily Average True Range (ATR) ChartTerns Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Terns Pharmaceuticals Inc. The current obv is -9,732,726.

Terns Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartTerns Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Terns Pharmaceuticals Inc. The current mfi is 51.76.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Terns Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartTerns Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Terns Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-28BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-10BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Terns Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Terns Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.960
Ma 20Greater thanMa 503.913
Ma 50Greater thanMa 1003.422
Ma 100Greater thanMa 2003.319
OpenGreater thanClose4.300
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Terns Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Terns Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Terns Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Terns Pharmaceuticals Inc

I send you an email if I find something interesting about Terns Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Terns Pharmaceuticals Inc.

Receive notifications about Terns Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.